Biotechnology company Moderna, Inc. (NASDAQ: MRNA) has reported a net loss for the fourth quarter of 2024, compared to a profit last year.
- Total revenue for the fourth quarter was $1.0 billion, compared to $2.8 billion in the same period of FY23
- Net product sales for the quarter were $938 million, reflecting a 66% year-over-year decrease
- The company reported a net loss of $1.1 billion for the December quarter, compared to net income of $217 million in Q4 2023
- On a per-share basis, net loss was $2.91 in the fourth quarter, compared to earnings per share of $0.55 in the prior-year quarter
- Cost of sales for Q4 came in at $739 million, which included third-party royalties of $45 million, inventory write-downs of $193 million, and wind-down costs of $259 million
- Research and development expenses decreased by 20% to $1.1 billion during the three months
- Cash, cash equivalents, and investments as of December 31, 2024, were $9.5 billion, compared to $9.2 billion as of September 30, 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Lamb Weston (LW) Q2 2026 Earnings: Key financials and quarterly highlights
Lamb Weston Holdings, Inc. (NYSE: LW) reported its second quarter 2026 earnings results today. Net sales inched up 1% year-over-year to $1.62 billion. Net sales at constant currency remained flat.
Paychex reports higher Q2 FY26 revenue and earnings; EPS beats estimates
Paychex Inc. (NASDAQ: PAYX) on Friday reported stronger-than-expected adjusted earnings for the second quarter of fiscal 2026. Revenues grew 18% year-over-year. The Rochester-based human capital management solutions provider reported revenues
Key highlights from NIKE’s (NKE) Q2 2026 earnings results
NIKE, Inc. (NYSE: NKE) reported revenues of $12.4 billion for the second quarter of 2026, which were up 1% on a reported basis and flat on a currency-neutral basis compared
